Eczema, also known as atopic dermatitis (AD), is an incurable, chronic condition that results in itchy, red, swollen, and cracked skin. Although eczema is not contagious, it is a long-lasting and itchy inflammatory skin disease that impacts both the physical and psychological quality of life for the people who suffer from it.
ADORING is a phase 3 clinical study evaluating the safety and efficacy of tapinarof cream, 1% for the topical treatment of moderate to severe eczema in children aged 2-17.
Although several treatment options are available to treat eczema, we are evaluating tapinarof for application to large areas of the body for long periods of time. Tapinarof is an investigational non-steroidal product that is being evaluated to determine if it may help control eczema signs and symptoms.